REgeneration of inner ear hair cells with GAmma-secretase INhibitors

The REGAIN project aims to develop and test a new drug administered to the ear to treat hearing loss caused by the loss of sensory hair cells in the inner ear.
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 634893.

Hearing loss: an unmet medical need

Hearing loss disables over 360 million people worldwide. Irrespective of its cause and severity, hearing loss can have a large impact on people’s health and well-being. The treatment of hearing loss is currently limited to the use of hearing aids or devices surgically implanted in the middle or inner ear. These devices often perform poorly in noisy environments and can be very costly. It has been estimated that the costs of untreated hearing loss are €213 billion in Europe alone each year.

Damage to the hair cells in the cochlea ("sensorineural hearing loss") is the major cause of hearing loss acquired later in life. The assumption has long been that sensorineural hearing loss is irreversible because once the hair cells in the cochlea become damaged, they cannot regenerate. However, recent studies in animals with hearing loss have shown that new and functioning hair cells can be generated through local treatment with a gamma-secretase inhibitor and improved hearing.

The REGAIN consortium is in the unique position to take the next crucial step in translation of these findings to the clinic, and test if this treatment is safe and improves hearing in people with sensorineural hearing loss.

Our Consortium

An international consortium of 7 partners has been awarded a €5,8 million European Commission Horizon 2020 grant to develop and test a new drug to treat hearing loss caused by the loss of sensory hair cells.
The consortium’s unique combination of expertise in hearing loss biology and drug development and clinical expertise in treating hearing loss allows REGAIN to advance from proof-of-concept to the clinic.